ResMed（RMD）2020Q3決算 好決算

ResMed（RMD）2020Q3

・発表日 2020/4/30 post-market
・売上 $769.46M +16.2% コンセンサス予想より+$48.04M
・non-GAAP EPS $1.29 +44.9% コンセンサス予想より+$0.21
・GAAP EPS $1.12
・GAAP net income $163M
・non-GAAP gross margin 60%（2019Q3 59.3%）
・決算発表後の株価 post-marketで+5.76%
・2020FYコンセンサス予想PER 162/4.11=39.41
・2021FYコンセンサス予想PER 162/4.57=35.44
・http://investors.resmed.com/investor-relations/events-and-presentations/default.aspx

人工呼吸器の売上増加と睡眠時無呼吸症候群用デバイスの売上低下の要素があり、今後の見通しは不透明とのことです。

As we look forward, there is uncertainty and it's not clear to what extent the upsurge in ventilation device and ventilation mask revenue will offset the decline in sleep device revenue and whether sleep mask revenue will maintain its growth or decelerate somewhat. But we know these facts, number one, the sleep apnea prevalence remains incredibly high, over 936 million people worldwide. And we know, fact two, that there is a backlog of diagnostic activity for sleep apnea and COPD that many clinics and physicians are preparing to ramp up their home sleep apnea testing, both now during the crisis and in the future as lockdowns are lifted around the world.

https://seekingalpha.com/article/4341809-resmed-inc-rmd-ceo-michael-farrell-on-q3-2020-results-earnings-call-transcript?part=single

決算発表メモ

Devices 売上 $391.5M +16%（為替を除くと+18%）

Masks and other 売上 $288.4M +17%（為替を除くと+18%）

Software as a service 売上 $89.6M +12%（為替を除くと+12%）

地域別では、

U.S., Canada and Latin America 売上 $483.1M +12%

Combined Europe, Asia and other markets 売上 $286.3M +23%（為替を除くと+27%）